

18 March 2021

RE: EudraCT 2017-001468-39

GS-US-313-1090: Phase 1b trial evaluating idelalisib in children and adolescents with relapsed or refractory diffuse large B-cell lymphoma or mediastinal B-cell lymphoma in combination with RICE

Gilead received a full product specific waiver from the European Medicines Agency's Paediatric Committee (PDCO) for the Zydelig Paediatric Investigational Plan (PIP) for all subsets of the paediatric population from birth to less than 18 years of age in the condition of treatment of mature B-cell neoplasm. The GS-US-313-1090 study was a commitment of the Zydelig (PIP), and therefore due to the receipt of the approved waiver, the study was closed and start up activities halted.

There were no subjects recruited into the study globally, and therefore no data were collected.